In Vivo Efficacy of SQ109 against <i>Leishmania donovani</i>, <i>Trypanosoma</i> spp. and <i>Toxoplasma gondii</i> and In Vitro Activity of SQ109 Metabolites

In Vivo Efficacy of SQ109 against <i>Leishmania donovani</i>, <i>Trypanosoma</i> spp. and <i>Toxoplasma gondii</i> and In Vitro Activity of SQ109 Metabolites

SQ109 is an anti-tubercular drug candidate that has completed Phase IIb/III clinical trials for tuberculosis and has also been shown to exhibit potent in vitro efficacy against protozoan parasites including <i>Leishmania</i> and <i>Trypanosoma cruzi</i> spp. However, its in v...

Full description

Bibliographic Details
Main Authors: Kyung-Hwa Baek, Trong-Nhat Phan, Satish R. Malwal, Hyeryon Lee, Zhu-Hong Li, Silvia N. J. Moreno, Eric Oldfield, Joo Hwan No
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Biomedicines
Subjects:
SQ109
in vivo
<i>Trypanosoma cruzi</i>
<i>Trypanosoma brucei</i>
<i>Leishmania donovani</i>
metabolites
Online Access:https://www.mdpi.com/2227-9059/10/3/670

Internet

https://www.mdpi.com/2227-9059/10/3/670

Similar Items